Last reviewed · How we verify
SKB571
At a glance
| Generic name | SKB571 |
|---|---|
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Study of SKB571 in Patients With Lung Cancer (PHASE2)
- A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors (PHASE1)
- A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SKB571 CI brief — competitive landscape report
- SKB571 updates RSS · CI watch RSS
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. portfolio CI